Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Data-driven identification of endophenotypes of Alzheimer’s disease progression: implications for clinical trials and therapeutic interventions

  Entire cohort Class 1 Class 2 Class 3
Number of participants 1160 119 888 153
Duration of follow-up (months) 12.8 ± 5.9 13.6 ± 4.2 13.3 ± 5.7 9.1 ± 6.7
Age 75.6 ± 8.1 73.1 ± 8.9 76.1 ± 7.8 74.7 ± 8.6
Gender
 Female 590 (50.9) 58 (48.7) 443 (49.9) 89 (58.2)
 Male 472 (40.7) 50 (42.0) 367 (41.3) 55 (35.9)
 Missing 98 (8.4) 11 (9.2) 78 (8.8) 9 (5.9)
Education 14.0 ± 3.2 14.8 ± 3.2 13.9 ± 3.3 14.0 ± 2.9
Race
 Asian 8 (0.7) 1 (0.8) 6 (0.7) 1 (0.7)
 African American 59 (5.1) 6 (5) 45 (5.1) 8 (5.2)
 White 1007 (86.8) 103 (86.8) 771 (86.8) 133 (86.9)
 Other 28 (2.4) 0 (0) 22 (2.5) 6 (3.9)
 Missing 58 (5) 9 (7.6) 44 (5) 5 (3.3)
Marital status
 Divorced 70 (6.0) 8 (6.7) 55 (6.2) 7 (4.6)
 Married 800 (69.0) 90 (75.6) 603 (67.9) 107 (69.9)
 Never married 26 (2.2) 3 (2.5) 22 (2.5) 1 (0.7)
 Widowed 243 (20.9) 16 (13.4) 195 (22.0) 32 (20.9)
 Missing 21 (1.8) 2 (1.7) 13 (1.5) 6 (3.9)
ApoE4 carriers (%)a 63.5 65.7 63.6 62.6
Statin users 311 (26.8) 23 (19.3) 254 (28.4) 34 (22.2)
Baseline ADAS-cog 23.6 ± 9.6 26.5 ± 6.9 20.4 ± 6.7 40.9 ± 6.3
  1. Baseline characteristics of participants in the entire cohort and in each of the resulting latent classes (in the three-class model). Data presented as mean ± standard deviation or n (%) unless stated otherwise
  2. ADAS-cog Alzheimer’s Disease Assessment Scale—cognitive subscale, ApoE4 Apolipoprotein E, allele 4
  3. aPercent of those participants with relevant information available